Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

10.36 -0.54 (-4.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immatics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
Immatics Announces Full Year 2023 Financial Results and Corporate Update
From https://immatics.com/
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Immatics Announces Pricing of $175 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Why Immatics Shares Are Rising Today
Immatics N.V. (NASDAQ: IMTX) shares are trading higher after the company announced  
Via Benzinga
Recap: Immatics Q1 Earnings
 
Via Benzinga
Why Immatics Stock Is Soaring Today
Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203. 
Via The Motley Fool
Immatics Announces Proposed Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Third Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
From https://immatics.com/
Via GlobeNewswire
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
From https://immatics.com/
Via GlobeNewswire
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Via ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Second Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
From https://immatics.com/
Via GlobeNewswire
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
From https://immatics.com/
Via GlobeNewswire
Top 5 Health Care Stocks That May Crash This Month
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Immatics Announces First Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
What's Going On With Immatics Shares Today
Immatics N.V. (NASDAQ: IMTX) shares are shooting higher today after it revealed an interim clinical data update for 11 patients with recurrent and/or refractory solid cancers treated with ACTengine... 
Via Benzinga
US Stocks Down; Chegg Crashes After Removing Guidance On ChatGPT Concerns
U.S. stocks traded lower this morning even as the Federal Reserve’s two-day meeting began. Following the market opening Tuesday, the Dow traded down 0.47% to 33,891.31 while the NASDAQ fell 0.12% to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration
Bristol-Myers Squibb Co (NYSE: BMY) announced  
Via Benzinga
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
From https://immatics.com/
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
 
Via Benzinga
Immatics Announces Full Year 2022 Financial Results and Corporate Update
From https://immatics.com/
Via GlobeNewswire
First Majestic Silver, Immatics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Immatics Announces Third Quarter 2022 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.